Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919633 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
A Phase 2 study of Hepatitis C, sponsored by Medtronic Corporate Technologies and New Ventures.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT00919633: Completed Phase 2 study of Hepatitis C, sponsored by Medtronic Corporate Technologies and New Ventures.
NCT00919633 is a Phase 2 study of Hepatitis C that has completed, run by Medtronic Corporate Technologies and New Ventures. The registered enrollment target is 116 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00919633, a Phase 2 study of Hepatitis C, has completed, sponsored by Medtronic Corporate Technologies and New Ventures.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with chronic hepatitis C infection as compared to patients who receive standard treatment.
Conditions Studied
Interventions
- DRUG interferon alfa-2b
- DRUG peginterferon alfa-2b
- DRUG ribavirin, USP
- DEVICE external drug infusion pump
Study Locations (1)
North Carolina
- Duke Clinical Research Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT00919633 record still lists
NCT00919633 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 4 interventions - of which interferon alfa-2b is the first listed.
NCT00919633 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00919633 about?
NCT00919633 is a clinical study titled "Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C". The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with chronic hepatitis C infection as compared to patients who receive stan...
What is the current status of trial NCT00919633?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2009-06. Estimated completion is 2012-07.
What conditions does trial NCT00919633 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00919633?
The interventions under investigation include: interferon alfa-2b (DRUG), peginterferon alfa-2b (DRUG), ribavirin, USP (DRUG), external drug infusion pump (DEVICE).
Who is sponsoring clinical trial NCT00919633?
This trial is sponsored by Medtronic Corporate Technologies and New Ventures, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00919633 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00919633's enrollment target sits among peer trials
116 52nd of 106 higher than 55 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia